NL-OMON24216尚未招募不适用
The role of Bosentan in fontan patients: improvement of aerobic capacity.
none0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. All adult Fontan patients are potentially eligible for this study.
排除标准
- •- Patients are not eligible for this study if the following inclusion criteria apply:
- •1. Systemic arterial pressure < 85 mmHg
研究者
相似试验
进行中（未招募）
不适用
The role of Bosentan in fontan patients: improvement of aerobic capacity - bosentan in fontan patientsTo study whether bosentan (endothelin receptor inhibitor) improves aerobic capacity (VO2max) and exercise performance in adult patients with a Fontan operation.MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-004533-21-NLICI50
已完成
2 期
Bosentan Therapy in Children With Functional Single VentricleCongenital Heart DefectsFunctional Single VentricleNCT01662037Shanghai Jiao Tong University School of Medicine34
已完成
不适用
Bosentan improves clinical Outcome of adults with congenital heart disease or mitral valve lesions who undergo CArdiac surgeryaangeboren hartafwijkingopen hart operatie risico1004697310007510NL-OMON36241Academisch Medisch Centrum110
进行中（未招募）
不适用
Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSACProgressive pulmonary sarcoidosisMedDRA version: 9.1Level: PTClassification code 10037430Term: Pulmonary sarcoidosisEUCTR2007-005117-18-ATMedical University of Vienna, Department of Clinical Pharmacology
终止
3 期
Bosentan Use in Patients With Diabetic NephropathyType 2 DiabetesNCT00638131Centre hospitalier de l'Université de Montréal (CHUM)1